Ruxolitinib 0.75% cream and ruxolitinib 1.5% cream are effective and well-tolerated in children aged 2 to 11 years with atopic dermatitis.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

Topical ruxolitinib cream shows promise as a treatment for inflammatory skin conditions, but lacks consistent data, indicating a need for further research into its use across various dermatologic ...

US-based biotechnology company Arcutis Biotherapeutics has enrolled the first child in an open-label Phase II trial of Zoryve ...

Outcomes were evaluated among children born between April 1980 and June 2019 by using data from 12 observational birth ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

A Google search on “diet and eczema” may be more misleading than helpful, warns pediatric dermatologist Sandipan Dhar.

The latest update atopic dermatitis guidelines include the new approval of lebrikizumab and the expanded use of baricitinib ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...

Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo ...

EMA’s veterinary medicinal products committee recommends marketing authorization to Elanco’s Zenrelia to treat atopic dermatitis in dogs: Greenfield, Indiana Monday, June 16, ...